Delcath Systems (NASDAQ:DCTH) and Imris (OTCMKTS:IMRSQ) Head to Head Contrast

Delcath Systems (NASDAQ:DCTH) and Imris (OTCMKTS:IMRSQ) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings.

Profitability

This table compares Delcath Systems and Imris’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.62%	0.51%	0.46%
Imris	N/A	N/A	N/A

Valuation and Earnings

This table compares Delcath Systems and Imris”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$90.44 million	4.89	$2.70 million	$0.01	1,281.00
Imris	N/A	N/A	N/A	N/A	N/A

Delcath Systems has higher revenue and earnings than Imris.

Insider & Institutional Ownership

61.1% of Delcath Systems shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Delcath Systems and Imris, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	1	1	5	0	2.57
Imris	0	0	0	0	0.00

Delcath Systems currently has a consensus target price of $22.17, suggesting a potential upside of 73.04%. Given Delcath Systems’ stronger consensus rating and higher possible upside, equities analysts clearly believe Delcath Systems is more favorable than Imris.

Summary

Delcath Systems beats Imris on 9 of the 9 factors compared between the two stocks.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

About Imris

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Winnipeg, Canada.